Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: meiragtx.com

Address:

655 Third Avenue, Suite 1115, New York, United States

HedgeAlerts Nov. 14 at 6:42 PM

Hedge Alert Live - Protect Your Portfolio Contract: $MGTX $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.30 - $0.40 Exit Price Target: $0.43 Profit Margin: +45% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

JarvisFlow Nov. 14 at 3:53 PM

RBC Capital has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Outperform with a price target of 16.

0 · Reply

slinghook67 Nov. 14 at 3:36 PM

$MGTX While not related to MeiraGTx in any way specific to science or tageted areas, it's worth noting that Cidara Therapeutics is being bought by Merck for $9.2B and are you ready for this, Cidara's market cap on Jan 1st of 2025 was ~$294M. Let that sink in. When Meira's long term value is truly recognized & appreciated we could very well have a similar explosion.

1 · Reply

JarvisFlow Nov. 14 at 1:25 PM

Chardan Capital has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Buy with a price target of 35.

0 · Reply

ErnieWorthing84 Nov. 14 at 1:04 PM

$MGTX Some influencer attention https://x.com/yaireinhorn/status/1989307667760677345

0 · Reply

HedgeAlerts Nov. 14 at 8:02 AM

Hedge Alert Live - Protect Your Portfolio Contract: $MGTX $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.30 - $0.40 Exit Price Target: $0.72 Profit Margin: +139% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 14 at 6:52 AM

0 · Reply

waterlock Nov. 14 at 12:27 AM

$MGTX the next catalyst is still $JNJ submission. It should be by the end of this year.

0 · Reply

BigDaddy_LongTrades Nov. 13 at 8:35 PM

$MGTX Meira folk... so is the concern just cash on hand?

2 · Reply

ErnieWorthing84 Nov. 13 at 6:25 PM

$MGTX Pain trial 1H26 nice to see; those usually move pretty fast

0 · Reply

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 12, 2025, 3:30 PM EST - 2 days ago

MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

Nov 10, 2025, 9:10 AM EST - 4 days ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 4 days ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 25, 2025, 3:48 AM EDT - 7 weeks ago

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

Aug 14, 2025, 8:00 AM EDT - 3 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 6 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 6 months ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 6 months ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 7 months ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Mar 25, 2025, 10:50 AM EDT - 8 months ago

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 13, 2025, 9:51 AM EDT - 8 months ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 8 months ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 8 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 6:30 AM EST - 9 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 4:09 PM EST - 10 months ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 8:30 AM EST - 10 months ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 3, 2024, 2:18 PM EST - 1 year ago

MeiraGTx Holdings: Behind The Recent Rally

Oct 15, 2024, 1:32 PM EDT - 1 year ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jul 15, 2024, 11:02 AM EDT - 1 year ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Feb 15, 2024, 8:23 AM EST - 1 year ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Jun 28, 2022, 7:00 AM EDT - 3 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

HedgeAlerts Nov. 14 at 6:42 PM

0 · Reply

JarvisFlow Nov. 14 at 3:53 PM

RBC Capital has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Outperform with a price target of 16.

0 · Reply

slinghook67 Nov. 14 at 3:36 PM

1 · Reply

JarvisFlow Nov. 14 at 1:25 PM

Chardan Capital has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Buy with a price target of 35.

0 · Reply

ErnieWorthing84 Nov. 14 at 1:04 PM

$MGTX Some influencer attention https://x.com/yaireinhorn/status/1989307667760677345

0 · Reply

HedgeAlerts Nov. 14 at 8:02 AM

0 · Reply

HedgeAlerts Nov. 14 at 6:52 AM

0 · Reply

waterlock Nov. 14 at 12:27 AM

$MGTX the next catalyst is still $JNJ submission. It should be by the end of this year.

0 · Reply

BigDaddy_LongTrades Nov. 13 at 8:35 PM

$MGTX Meira folk... so is the concern just cash on hand?

2 · Reply

ErnieWorthing84 Nov. 13 at 6:25 PM

$MGTX Pain trial 1H26 nice to see; those usually move pretty fast

0 · Reply

ErnieWorthing84 Nov. 13 at 2:04 PM

$MGTX https://www.nejm.org/doi/full/10.1056/NEJMsb2512695

0 · Reply

waterlock Nov. 13 at 1:52 PM

$MGTX only 17 m left? Why do I remember that the number is much higher than that?

2 · Reply

ErnieWorthing84 Nov. 13 at 1:18 PM

$MGTX First ribo indication going to clinic. They're looking to edge out Myalept

1 · Reply

ErnieWorthing84 Nov. 12 at 10:47 PM

$MGTX https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E

0 · Reply

Bogy99 Nov. 12 at 9:28 PM

$MGTX according to Bloomberg we have earnings tomorrow. Usually uneventful , but I’m hoping to see what progress they are making on xerestomia and also hoping to hear something about riboswitch. We were promised a Ribo day last year, remember . Beyond that just making sure we got paid by Holegen.

0 · Reply

ErnieWorthing84 Nov. 12 at 4:28 PM

$MGTX

2 · Reply

BigDaddy_LongTrades Nov. 12 at 4:26 PM

$MGTX Honestly, this should be closer to 1 dollar based on all the positive things Meira has done. That's how stocks work right?

0 · Reply

Sharkfire Nov. 12 at 2:39 PM

$MGTX what time is earnings ?

2 · Reply

DARKP00L Nov. 11 at 5:40 PM

$MGTX 12:22 on Nov. 11 2025 Piper Sandler Maintains Overweight on MeiraGTx Hldgs, Raises Price Target to $30 #tradeideas

0 · Reply

JarvisFlow Nov. 11 at 5:22 PM

Piper Sandler has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Overweight with a price target of 30.

0 · Reply

ErnieWorthing84 Nov. 11 at 2:47 PM

$MGTX

1 · Reply

JarvisFlow Nov. 11 at 1:07 PM

Chardan Capital has updated their rating for MeiraGTx Hldgs ( $MGTX ) to Buy with a price target of 35.

0 · Reply

Market Cap	696.67M
Revenue (ttm)	33.28M
Net Income (ttm)	-147.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-444.08%
Debt to Equity Ratio	24.92

Volume	486,769
Avg Vol	442,252
Day's Range	N/A - N/A
Shares Out	80.45M
Stochastic %K	16%
Beta	1.35
Analysts	Strong Sell
Price Target	$24.33